Price (delayed)
$5.69
Market cap
$118.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.99
Enterprise value
$86.14M
Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate,
There are no recent dividends present for ADVM.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.